Capricor Therapeutics, a biotechnology company focused on developing innovative cell and exosome-based therapeutics for rare diseases, has announced significant regulatory progress for its Duchenne Muscular Dystrophy (DMD) program. The company reported the successful completion of a Pre-License Inspection (PLI) of its manufacturing facility located in San Diego by the U.S. Food and Drug Administration (FDA) for its lead therapeutic candidate, Deramiocel.
Deramiocel is currently undergoing review for approval through a Biologics License Application (BLA), aimed at providing a promising treatment option for patients suffering from DMD, a progressive muscular disorder that primarily affects young males and leads to severe muscle degeneration and weakness.
During the inspection, the FDA identified several observations detailed in a Form 483, which highlights areas of concern regarding compliance with current Good Manufacturing Practices (cGMP). Importantly, the company has reported that its responses to these observations did not necessitate any material modifications to its manufacturing processes or facility design. The comments from the FDA primarily pertained to standard quality systems and documentation practices, which the company is addressing with the intention of ensuring compliance.
Capricor Therapeutics expressed confidence in the ability of its San Diego facility to meet the FDA’s licensing requirements, indicating proactive measures to enhance its operational practices. The company remains optimistic about the potential approval and subsequent commercial launch of Deramiocel, which could significantly impact the treatment landscape for DMD patients.
As the company moves forward, industry stakeholders will be closely monitoring Capricor’s progress in addressing the FDA’s observations and the subsequent steps towards the potential commercialization of Deramiocel. The successful navigation of this regulatory pathway could pave the way for future advancements in biotherapeutics for rare diseases.
Comments